28 Apr CHARLES CHIU
[et_pb_section admin_label=”section”][et_pb_row admin_label=”row”][et_pb_column type=”1_4″][et_pb_image admin_label=”Image” src=”http://www.pmwcintl.xyz/wp-content/uploads/2016/04/charles-chiu.jpg” show_in_lightbox=”off” url_new_window=”off” use_overlay=”off” animation=”left” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] [/et_pb_image][/et_pb_column][et_pb_column type=”3_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]
M.D., PH.D, ASSOCIATE. PROF., UCSF LAB. MED. & INFEC. DISEASES, DIRECTOR, UCSF-ABBOTT VIRAL DX & DISCOVERY CENTER
Dr. Chiu is an expert in the development and implementation of advanced genomic technologies for pathogen discovery and clinical diagnostics, including microarrays and next-generation sequencing, for a variety of blood-borne infections. His efforts in Lyme disease focus on the development of diagnostics for both pathogen detection and host response. He uses next-generation sequencing and has developed the “TickChip” to directly detect the RNA of Lyme bacteria and other tick-borne pathogens. He is also using RNA-sequencing technology to detect and identify a diagnostic profile of the body’s response to being infected by Lyme disease. He recently published in the highly prestigious New England Journal of Medicine, as described in a New York Times article, about the ability to uniquely and expeditiously diagnose a disease caused by an uncommon bacterial pathogen, Leptospira santarosai.